|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体
|
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
DE69740140D1
(de)
|
1996-07-24 |
2011-04-14 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
|
|
TR200101500T2
(tr)
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
RU2312861C2
(ru)
|
2002-03-05 |
2007-12-20 |
Мерк Фросст Кэнада Лтд. |
Ингибиторы катепсин-цистеинпротеазы
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
WO2006028958A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
|
CA2822094C
(en)
|
2005-08-31 |
2015-10-27 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
|
US8445198B2
(en)
|
2005-12-01 |
2013-05-21 |
Medical Prognosis Institute |
Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
US20070128636A1
(en)
|
2005-12-05 |
2007-06-07 |
Baker Joffre B |
Predictors Of Patient Response To Treatment With EGFR Inhibitors
|
|
AU2007290407A1
(en)
|
2006-08-30 |
2008-03-06 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CN101578277A
(zh)
*
|
2006-08-30 |
2009-11-11 |
细胞基因公司 |
5-取代的异二氢吲哚化合物
|
|
US20090280493A1
(en)
|
2006-09-08 |
2009-11-12 |
Siemens Healthcare Diagnostics Inc. |
Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia
|
|
US8648096B2
(en)
|
2006-09-15 |
2014-02-11 |
Celgene Corporation |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
|
CA2681633C
(en)
|
2007-03-20 |
2018-01-09 |
Celgene Corporation |
4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
CA2957226C
(en)
*
|
2008-10-29 |
2018-08-14 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer
|
|
US8545515B2
(en)
|
2009-09-23 |
2013-10-01 |
Intuitive Surgical Operations, Inc. |
Curved cannula surgical system
|
|
SG183257A1
(en)
|
2010-02-11 |
2012-09-27 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
US9662319B2
(en)
|
2011-03-11 |
2017-05-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs
|
|
EP2699909A1
(en)
|
2011-04-18 |
2014-02-26 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
|
DK2702172T3
(da)
|
2011-04-29 |
2020-04-06 |
Univ Aarhus |
Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer
|
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
WO2014028445A2
(en)
|
2012-08-14 |
2014-02-20 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
MX363437B
(es)
|
2012-12-13 |
2019-03-22 |
Novartis Ag |
Pirimido-4,5-b]-quinolina-4,5 (3h,10h)-dionas como supresoras de mutacion sin sentido.
|
|
CA2908954C
(en)
|
2013-04-17 |
2021-08-03 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
|
|
CA2949048A1
(en)
|
2013-05-22 |
2014-11-27 |
The Regents Of The University Of California |
Aurora kinase inhibitors
|
|
WO2015006299A1
(en)
|
2013-07-08 |
2015-01-15 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical formulations of tranexamic acid and their use
|
|
WO2015085172A2
(en)
|
2013-12-06 |
2015-06-11 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
WO2015123377A1
(en)
|
2014-02-12 |
2015-08-20 |
Dana-Farber Cancer Institute, Inc. |
P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses
|
|
JP6576942B6
(ja)
|
2014-03-03 |
2019-11-27 |
マドリガル ファーマシューティカルズ インコーポレイテッド |
標的治療薬
|
|
MA39483A
(fr)
|
2014-03-18 |
2015-09-24 |
Synta Pharmaceuticals Corp |
Agents thérapeutiques cibles
|
|
EP4649963A3
(en)
|
2014-04-14 |
2026-05-13 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
AU2015305449B2
(en)
|
2014-08-22 |
2021-05-06 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
JP2017538104A
(ja)
|
2014-10-07 |
2017-12-21 |
セルジーン コーポレイション |
癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用
|
|
WO2016065139A1
(en)
|
2014-10-24 |
2016-04-28 |
Fl Therapeutics Llc |
3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
|
|
NZ731789A
(en)
|
2014-10-30 |
2019-04-26 |
Kangpu Biopharmaceuticals Ltd |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
GB201516243D0
(en)
|
2015-09-14 |
2015-10-28 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN105175285B
(zh)
|
2015-10-10 |
2017-05-03 |
山东大学 |
多靶点型他米巴罗汀衍生物及其制备方法和应用
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
|
TWI782395B
(zh)
|
2016-01-08 |
2022-11-01 |
美商西建公司 |
抗增生化合物,及其醫藥組合物及用途
|
|
EP3399980B1
(en)
|
2016-01-08 |
2025-07-16 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
US10052315B2
(en)
|
2016-01-08 |
2018-08-21 |
Celgene Corporation |
Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
|
RU2018132559A
(ru)
|
2016-02-16 |
2020-03-17 |
Массачусетс Инститьют Оф Текнолоджи |
Связывающие молекулы для max в качестве модуляторов myc и их применения
|
|
CN109153644B
(zh)
|
2016-03-16 |
2022-10-21 |
H·李·莫菲特癌症中心研究有限公司 |
用以增强效应t细胞功能的针对cereblon的小分子
|
|
EP3440082A1
(en)
|
2016-04-06 |
2019-02-13 |
The Regents of The University of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
CN109152933B
(zh)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
CN121974842A
(zh)
|
2016-05-10 |
2026-05-05 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
|
US11285218B2
(en)
|
2016-06-23 |
2022-03-29 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
|
|
AU2017281525B2
(en)
|
2016-06-23 |
2021-01-21 |
Dana-Farber Cancer Institute, Inc. |
Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
|
|
CA3036834A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
ES2857743T3
(es)
|
2016-09-13 |
2021-09-29 |
Univ Michigan Regents |
1,4-diazepinas fusionadas como degradadores de proteína BET
|
|
SI3526202T1
(sl)
|
2016-10-11 |
2025-04-30 |
Arvinas Operations, Inc. |
Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
US10689366B2
(en)
|
2016-11-01 |
2020-06-23 |
Cornell University |
Compounds for MALT1 degredation
|
|
AU2017363257B2
(en)
|
2016-11-22 |
2021-08-19 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
US10842878B2
(en)
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
CA3042294A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
EP3329923A1
(en)
|
2016-12-02 |
2018-06-06 |
University of Copenhagen |
The potential of crbn-independent imid resensitization by epigenetic therapy
|
|
CA3045037A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
JP2020504711A
(ja)
|
2016-12-21 |
2020-02-13 |
バイオセリックス, インコーポレイテッド |
タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
US12023385B2
(en)
|
2017-02-08 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
WO2018169777A1
(en)
|
2017-03-14 |
2018-09-20 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
CN108929307A
(zh)
|
2017-05-22 |
2018-12-04 |
苏州偶领生物医药有限公司 |
一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
|
|
EP4201399A3
(en)
|
2017-06-30 |
2023-08-09 |
Celgene Corporation |
Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
|
|
KR101904287B1
(ko)
|
2017-07-03 |
2018-10-04 |
효성전기주식회사 |
단순한 버스바 구조를 갖는 브러쉬리스 모터의 결선방법
|
|
JP7258009B2
(ja)
|
2017-07-10 |
2023-04-14 |
セルジーン コーポレイション |
抗増殖化合物及びその使用方法
|
|
CN107698575A
(zh)
|
2017-09-26 |
2018-02-16 |
中国药科大学 |
cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US20210069356A1
(en)
|
2018-01-02 |
2021-03-11 |
Celgene Corporation |
Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3744719B1
(en)
|
2018-01-25 |
2023-06-07 |
Fujimoto Co., Ltd. |
Thiophene derivative and use thereof
|
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
|
BR112020017053A2
(pt)
|
2018-02-21 |
2020-12-15 |
Celgene Corporation |
Anticorpos que se ligam ao bcma e usos dos mesmos
|
|
CA3091041A1
(en)
|
2018-02-22 |
2019-08-29 |
Ichan School Of Medicine At Mount Sinai |
Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
|
|
WO2019170150A1
(zh)
|
2018-03-09 |
2019-09-12 |
上海科技大学 |
蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
|
|
WO2019177902A1
(en)
|
2018-03-10 |
2019-09-19 |
Yale University |
Modulators of btk proteolysis and methods of use
|
|
US10584133B2
(en)
|
2018-03-30 |
2020-03-10 |
Biotheryx, Inc. |
Thienopyrimidinone compounds
|
|
AU2019249849C1
(en)
|
2018-04-01 |
2022-09-29 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
EP3778590A4
(en)
|
2018-04-09 |
2021-12-22 |
ShanghaiTech University |
ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE
|
|
CA3095912A1
(en)
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN118344338A
(zh)
|
2018-04-23 |
2024-07-16 |
细胞基因公司 |
取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
|
|
US10905684B2
(en)
|
2018-06-13 |
2021-02-02 |
Biotheryx, Inc. |
Aminoamide compounds
|
|
US11191769B2
(en)
|
2018-06-13 |
2021-12-07 |
Biotheryx, Inc. |
Fused thiophene compounds
|
|
AU2019294835B2
(en)
|
2018-06-29 |
2025-04-17 |
Dana-Farber Cancer Institute, Inc. |
Ligands to cereblon (CRBN)
|
|
CN110684015A
(zh)
|
2018-07-06 |
2020-01-14 |
四川大学 |
靶向alk的protac及其应用
|
|
EP3820532A4
(en)
|
2018-07-11 |
2022-04-06 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
|
|
US11045458B2
(en)
|
2018-07-23 |
2021-06-29 |
Wisconsin Alumni Research Foundation |
Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them
|
|
AU2019309909A1
(en)
|
2018-07-23 |
2021-02-04 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020023782A1
(en)
|
2018-07-27 |
2020-01-30 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
CN119219628A
(zh)
|
2018-09-07 |
2024-12-31 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
CA3109617A1
(en)
|
2018-09-27 |
2020-04-02 |
Dana-Farber Cancer Institute, Inc. |
Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
|
|
CA3121667A1
(en)
|
2018-09-30 |
2020-04-02 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Isoindoline compound, preparation method, pharmaceutical composition and use thereof
|
|
US20210293788A1
(en)
|
2018-10-16 |
2021-09-23 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Method for identifying a chemical compound or agent inducing ubiquitination of a protein of interest
|
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
|
JP2022507267A
(ja)
|
2018-11-13 |
2022-01-18 |
バイオセリックス, インコーポレイテッド |
置換イソインドリノン
|
|
WO2020103878A1
(zh)
|
2018-11-21 |
2020-05-28 |
上海科技大学 |
Er蛋白调节剂及其应用
|
|
WO2020118098A1
(en)
|
2018-12-05 |
2020-06-11 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
|
AU2019392231B2
(en)
|
2018-12-06 |
2022-10-20 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
|
|
DK3908281T3
(da)
|
2019-01-09 |
2024-10-21 |
Celgene Corp |
Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
|
|
GB2580675A
(en)
|
2019-01-23 |
2020-07-29 |
Wheelright Ltd |
Tyre sidewall imaging method
|
|
WO2020160192A1
(en)
*
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
KR102876423B1
(ko)
|
2019-02-07 |
2025-10-24 |
한국화학연구원 |
표적 단백질 eed 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 eed, ezh2, 또는 prc2 관련 질환의 예방 또는 치료용 약학적 조성물
|
|
EP3924350A1
(en)
*
|
2019-02-13 |
2021-12-22 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
CN113646002A
(zh)
|
2019-02-27 |
2021-11-12 |
上海睿跃生物科技有限公司 |
环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
|
|
WO2020200291A1
(en)
|
2019-04-02 |
2020-10-08 |
Cullgen (Shanghai) , Inc. |
Compounds and methods of treating cancers
|
|
ES3055186T3
(en)
|
2019-04-04 |
2026-02-10 |
Dana Farber Cancer Inst Inc |
Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
|
|
CN114423463B
(zh)
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
CN114502543A
(zh)
|
2019-05-24 |
2022-05-13 |
拜欧斯瑞克斯公司 |
靶向蛋白化合物、其药物组合物及治疗应用
|
|
AR119057A1
(es)
|
2019-05-31 |
2021-11-17 |
Celgene Corp |
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
EP3986470A4
(en)
|
2019-06-18 |
2023-10-04 |
Dana-Farber Cancer Institute, Inc. |
TARGETED SMALL MOLECULE BROMO/ACETYL PROTEINS AND THEIR USES
|
|
CN110372669B
(zh)
|
2019-06-19 |
2020-11-24 |
浙江省医学科学院 |
一种基于crbn配体诱导egfr降解的化合物及其制备方法、药物组合物和应用
|
|
CN110305126A
(zh)
|
2019-06-19 |
2019-10-08 |
浙江省医学科学院 |
一种基于crbn配体诱导cdk4/6降解的化合物及其制备方法、药物组合物和应用
|
|
CN110204543B
(zh)
|
2019-06-27 |
2022-03-29 |
江苏省中医药研究院 |
一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物
|
|
WO2020264490A1
(en)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
US20220281831A1
(en)
|
2019-07-15 |
2022-09-08 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
|
US20230093080A1
(en)
|
2019-07-15 |
2023-03-23 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2021011871A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
US12558427B2
(en)
|
2019-07-17 |
2026-02-24 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
JP2021020879A
(ja)
|
2019-07-30 |
2021-02-18 |
学校法人東京医科大学 |
p63スプライシングバリアントの分解剤およびその用途
|
|
WO2021022163A2
(en)
|
2019-07-31 |
2021-02-04 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
CN114174281B
(zh)
|
2019-08-05 |
2025-02-07 |
达纳-法伯癌症研究公司 |
细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途
|
|
AU2020336381A1
(en)
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
US20230202980A1
(en)
|
2019-08-30 |
2023-06-29 |
National University Of Singapore |
N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer
|
|
TW202124374A
(zh)
|
2019-09-13 |
2021-07-01 |
美商拜歐斯瑞克斯公司 |
Ras蛋白降解劑、其醫藥組合物及其治療應用
|
|
JP7874541B2
(ja)
|
2019-09-16 |
2026-06-16 |
ノバルティス アーゲー |
接着分解剤及びその使用方法
|
|
CN110563703B
(zh)
|
2019-09-18 |
2021-04-09 |
浙江省医学科学院 |
基于crbn配体诱导parp-1降解的化合物及制备方法和应用
|
|
JP7502425B2
(ja)
|
2019-10-01 |
2024-06-18 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Brm標的化化合物および関連使用方法
|
|
JP7724394B2
(ja)
|
2019-10-09 |
2025-08-18 |
モンテ ローザ セラピューティクス アーゲー |
イソインドリノン化合物
|
|
CN110734426B
(zh)
|
2019-10-28 |
2021-02-05 |
浙江省医学科学院 |
乙酰胆碱酯酶降解化合物及其制备方法和应用
|
|
BR112022007996A2
(pt)
|
2019-10-28 |
2022-07-05 |
Celgene Corp |
Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
|
|
US20220378773A1
(en)
|
2019-10-28 |
2022-12-01 |
Celgene Corporation |
Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
|
|
CN112812109B
(zh)
|
2019-11-18 |
2022-06-21 |
中国科学院微生物研究所 |
化合物DaP-01及其制备方法和应用
|
|
JP7871189B2
(ja)
|
2019-12-17 |
2026-06-08 |
オリオニス バイオサイエンシズ,インコーポレイテッド |
タンパク質の動員および/または分解を調節する化合物
|
|
US20230099031A1
(en)
|
2019-12-17 |
2023-03-30 |
Orionis Biosciences, Inc. |
Bifunctional agents for protein recruitment and/or degradation
|
|
US20230357222A1
(en)
|
2020-03-17 |
2023-11-09 |
Dana-Farber Cancer Institute, Inc. |
Selective small molecule degraders of cereblon
|
|
CN122562781A
(zh)
|
2020-10-07 |
2026-08-14 |
上海睿跃生物科技有限公司 |
治疗癌症的化合物和方法
|
|
EP4232023A4
(en)
|
2020-10-26 |
2025-11-12 |
Dana Farber Cancer Inst Inc |
COMPOUNDS FOR THE TARGETED DEGRADATION OF KINASE PROTEINS
|
|
CN117242060B
(zh)
*
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
WO2022152822A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Treatment of myc-driven cancers with gspt1 degraders
|
|
EP4313047A1
(en)
|
2021-03-22 |
2024-02-07 |
Monte Rosa Therapeutics, Inc. |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
WO2023069708A1
(en)
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and uses thereof
|
|
WO2023069731A1
(en)
|
2021-10-22 |
2023-04-27 |
Monte Rosa Therapeutics, Inc. |
Compounds that mediate protein degradation and methods of use thereof
|
|
CN119630648A
(zh)
|
2022-07-14 |
2025-03-14 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮衍生物的制备方法及其晶形
|